Medigene AG (ETR:MDG1 – Get Free Report) traded up 1.4% on Tuesday . The company traded as high as €1.10 ($1.13) and last traded at €1.02 ($1.05). 27,090 shares were traded during mid-day trading, a decline of 91% from the average session volume of 306,207 shares. The stock had previously closed at €1.01 ($1.04).
Medigene Stock Performance
The firm has a market capitalization of $15.06 million, a P/E ratio of -0.84, a price-to-earnings-growth ratio of 7.12 and a beta of 0.84. The company has a 50-day moving average of €1.32 and a 200-day moving average of €1.45. The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.94.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Recommended Stories
- Five stocks we like better than Medigene
- How to Read Stock Charts for Beginners
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What is the Dow Jones Industrial Average (DJIA)?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
